Pediatrics Clinical Trial
Official title:
Multicenter Safety Evaluation of Human Rabies Immune Globulin 300 IU/mL in Children
NCT number | NCT05382650 |
Other study ID # | PRO00028137 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | February 22, 2023 |
Est. completion date | July 2024 |
This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (PEP) in the ED.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A to 17 Years |
Eligibility | Inclusion Criteria 1. Received HRIG 300 IU/mL for rabies PEP during an ED encounter visit 2. Aged =17 years Exclusion Criteria 1. HRIG 300 IU/mL dose given is <18 IU/kg or >22 IU/kg 2. Patient is admitted or transferred to a hospital from the ED for further management of injuries related to the animal exposure 3. Patient has a history of rabies vaccine or rabies immune globulin administration 4. Legally authorized representative (parent) does not speak English if patient is <7 years old 5. Legally authorized representative (parent) or patient does not speak English if patient is 7 to 17 years old 6. Inability to obtain consent 1. More than 3 days passed since HRIG 300 IU/mL administration prior to screen 2. Unable to contact legally authorized representative (parent) and/or patient within 3 days of HRIG 300 IU/mL administration 3. Legally authorized representative (parent) and/or patient declined participation 7. Administration sites for HRIG are unknown |
Country | Name | City | State |
---|---|---|---|
United States | Houston Methodist | Houston | Texas |
United States | Texas Children's Hospital | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The Methodist Hospital Research Institute | Grifols Biologicals, LLC |
United States,
Hanna K, Cruz MC, Mondou E, Corsi E, Vandeberg P. Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified. Clin Pharmacol. 2018 Jun 26;10:79-88. doi: 10.2147/CPAA.S166454. eCollection 2018. — View Citation
Hwang GS, Rizk E, Bui LN, Iso T, Sartain EI, Tran AT, Swan JT. Adherence to guideline recommendations for human rabies immune globulin patient selection, dosing, timing, and anatomical site of administration in rabies postexposure prophylaxis. Hum Vaccin Immunother. 2020;16(1):51-60. doi: 10.1080/21645515.2019.1632680. Epub 2019 Aug 1. — View Citation
Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008 May 23;57(RR-3):1-28. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of local and systemic adverse events (AEs) within 2 days of HRIG 300 IU/mL administration | Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration | Within 2 days of HRIG 300 IU/mL administration | |
Secondary | Cumulative incidence of all local and systemic AEs within 10 days of HRIG 300 IU/mL administration | Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration | Within 10 days of HRIG 300 IU/mL administration | |
Secondary | Cumulative incidence of all local and systemic AEs within 30 days of HRIG 300 IU/mL administration | Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration | Within 30 days of HRIG 300 IU/mL administration | |
Secondary | Cumulative incidence of all local and systemic serious adverse events (SAEs) within 30 days of HRIG 300 IU/mL administration | Proportion of patients with 1 or more SAE deemed as possibly/definitely related to HRIG 300 IU/mL administration. An AE is considered "serious" if any of the following outcomes occur:
Death Life-threatening AE (life-threatening in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) In-patient hospitalization or prolongation of existing hospitalization A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions An important medical event (refers to events which may not be immediately life-threatening, or result in death, or hospitalization, but from medical and scientific judgment, may jeopardize the participant or/and may require medical or surgical intervention to prevent one of the other outcomes listed above). |
Within 30 days of HRIG 300 IU/mL administration | |
Secondary | Type and severity of individual local and systemic AEs detected within 30 days of HRIG 300 IU/mL administration | Proportions of AEs that are local vs systemic and proportions of AEs that are mild, moderate, or severe among AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration | Within 30 days of HRIG 300 IU/mL administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05975658 -
WIReD: Wireless Interstage Remote Device Study
|
||
Completed |
NCT03921346 -
Reducing Prehospital Medication Errors & Time to Drug Delivery by EMS During Simulated Pediatric CPR
|
N/A | |
Completed |
NCT04301206 -
Videos and Simple Text to Empower Parents to Handle Their Sick Children
|
N/A | |
Not yet recruiting |
NCT04087070 -
Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
|
||
Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
Recruiting |
NCT05480930 -
Improving Nighttime Access to Care and Treatment; Part 4-Haiti
|
N/A | |
Not yet recruiting |
NCT05815563 -
Validation of Peripheral Perfusion Index in Predicting Successful Supraclavicular Brachial Plexus Block in Pediatrics
|
||
Recruiting |
NCT02556541 -
Ultrasound-guided Peripheral Vascular Access in Children
|
N/A | |
Recruiting |
NCT02908113 -
Visual Perception in Preterm Infants
|
N/A | |
Not yet recruiting |
NCT01678066 -
A Prospective Study to Bilaterally Compare a Non-Invasive Cardiac Output Monitor
|
N/A | |
Completed |
NCT04993599 -
Evaluation of Social Robot Usability for Pediatric Patients and Carers
|
N/A | |
Completed |
NCT05537168 -
Bayesian Networks in Pediatric Cardiac Surgery
|
||
Completed |
NCT01603628 -
BOTOX® Treatment in Pediatric Lower Limb Spasticity
|
Phase 3 | |
Completed |
NCT01603615 -
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
|
Phase 3 | |
Completed |
NCT06098105 -
Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block vs Laparoscopic Intraperitoneal Instillation of Local Anesthetic in Pediatrics
|
N/A | |
Completed |
NCT01418846 -
Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients
|
N/A | |
Completed |
NCT01460329 -
Comparing Cardiac Output Measurements in Critically Ill Children Using USCOM and Transthoracic ECHO
|
N/A | |
Withdrawn |
NCT00666393 -
An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients
|
Phase 3 | |
Recruiting |
NCT03337581 -
Pharmacodynamics and Pharmacokinetics of Dexmedetomidine in Pediatric
|
Phase 4 | |
Recruiting |
NCT05275881 -
Impact of Virtual Reality in Pediatric Hematology and Oncology
|
N/A |